investor.relypsa.com
Investor Relations - Relypsa, Inc.The Investor Relations website contains information about Relypsa, Inc. business for stockholders, potential investors, and financial analysts.
http://investor.relypsa.com/
The Investor Relations website contains information about Relypsa, Inc. business for stockholders, potential investors, and financial analysts.
http://investor.relypsa.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.2 seconds
16x16
PAGES IN
THIS WEBSITE
16
SSL
EXTERNAL LINKS
65
SITE IP
206.200.251.19
LOAD TIME
0.246 sec
SCORE
6.2
Investor Relations - Relypsa, Inc. | investor.relypsa.com Reviews
https://investor.relypsa.com
The Investor Relations website contains information about Relypsa, Inc. business for stockholders, potential investors, and financial analysts.
investor.relypsa.com
Printed Materials - Relypsa, Inc.
http://investor.relypsa.com/printed-materials.cfm
To receive printed material by postal mail, please complete the following form. Fixed Income Analyst (sell-side). Fixed Income Analyst (buy-side). Portfolio Manager (Fixed Income). Holy See (Vatican City). Saint Kitts And Nevis. Saint Vincent and Grenadines. Turks And Caicos Islands. Virgin Islands (U.S.). UPS Next Day Air. Required for express delivery. Listen to audio version. Type in number *. I am interested in receiving investor relations notifications. Our Innovative Polymer Science. Hane Chow, Inc.
Events & Presentations - Relypsa, Inc.
http://investor.relypsa.com/events.cfm
Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. Jul 12, 2016. Cantor Fitzgerald 2nd Annual Healthcare Conference. May 10, 2016. Bank of America Merrill Lynch 2016 Health Care Conference. Speaker: John A Orwin. May 4, 2016. Q1 2016 Relypsa, Inc. Earnings Conference Call. Mar 8, 2016. 36th Annual Cowen Health Care Conference. Feb 24, 2016. Q4 2015 Relypsa, Inc. Earnings Conference Call. Add file to Briefcase. Our Innovative Polymer Science.
Financials & Filings - Relypsa, Inc.
http://investor.relypsa.com/financials.cfm
First Quarter 2016 Financial Results. Q1 2016 Relypsa, Inc. Earnings Conference Call. Relypsa Reports First Quarter 2016 Financial Results. File is in Briefcase. File is in Briefcase. Apr 28, 2016. File is in Briefcase. Apr 22, 2015. File is in Briefcase. Feb 25, 2016. File is in Briefcase. Mar 12, 2015. File is in Briefcase. Aug 4, 2016. File is in Briefcase. May 4, 2016. File is in Briefcase. Add PDF file to Briefcase. Annual Reports and Proxies. Our Innovative Polymer Science. Hane Chow, Inc.
Press Releases - Relypsa, Inc.
http://investor.relypsa.com/releases.cfm
Aug 30, 2016. Relypsa Announces Phase 4 Study Shows Veltassa Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia. File is in Briefcase. Jul 21, 2016. Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa. Acquisition Strengthens Galenica's Business Unit, Vifor Pharma - Galenica will commence a tender offer to acquire all issued and outstand. File is in Briefcase. Jul 18, 2016. Relypsa Announces New Employment Inducement Grants. REDWO...
Corporate Governance - Relypsa, Inc.
http://investor.relypsa.com/corporate-governance.cfm
File is in Briefcase. Nominating and Corporate Governance Committee Charter. File is in Briefcase. Code of Business Conduct and Ethics. File is in Briefcase. File is in Briefcase. File is in Briefcase. File is in Briefcase. Add file to Briefcase. Our Innovative Polymer Science. Our Innovative Polymer Science. Hane Chow, Inc.
TOTAL PAGES IN THIS WEBSITE
16
Our Innovative Polymer Science | Relypsa, Inc.
http://www.relypsa.com/pipeline/patiromer-fos
Using Polymers to Develop Novel Medicines. Polymers are large molecules made up of repeating structural units. They exist in nature – in the form of proteins and starch, for example – but can also be manufactured in a laboratory for a variety of purposes and applications such as plastics and coatings. Relypsa’s Innovative Approach to Developing Polymeric Medicines. Since we were founded, we have focused on using our proprietary polymer drug discovery and optimization technology, which involves an efficie...
What is Hyperkalemia? | Relypsa, Inc.
http://www.relypsa.com/pipeline/hyperkalemia
Hyperkalemia: High Blood Potassium Levels. Hyperkalemia, or high potassium levels in the blood, is an asymptomatic condition that if not treated can cause abnormal heart rhythms and even sudden death. Common in People with Chronic Kidney Disease and/or Heart Failure. As the number of people with these conditions continues to climb, primarily due to the aging of the population, more people will develop hyperkalemia:. Hyperkalemia as a Side Effect. Long-Term Management Has Been Challenging. As their kidney...
For Media | Relypsa, Inc.
http://www.relypsa.com/media
Committed to Providing the Media with Timely and Accurate Information. This section offers the following resources for media professionals:. Vice President, Corporate Communications and Investor Relations. Our Innovative Polymer Science. Our Innovative Polymer Science. Hane Chow, Inc.
Mission & Values | Relypsa, Inc.
http://www.relypsa.com/about/mission-values
To improve patients’ lives through the discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches. We focus our efforts on improving the lives of patients. We set ambitious goals and deliver quality results. We do what‘s right, acting in the best interests of patients and other stakeholders. We passionately seek and apply better solutions to new and existing scientific and business challenges. Charitable Contributions and Sponsorships. Hane Chow, Inc.
Our Culture | Relypsa, Inc.
http://www.relypsa.com/careers
Working Together at Relypsa. At Relypsa, we put patients first. We make decisions based on patients’ well-being and partner with medical foundations to support their near- and long-term patient initiatives. We are committed to providing patients in need access to our medicines. Our Innovative Polymer Science. Our Innovative Polymer Science. Hane Chow, Inc.
Digital Library | Relypsa, Inc.
http://www.relypsa.com/media/photo-library
Our Innovative Polymer Science. Our Innovative Polymer Science. Hane Chow, Inc.
Veltassa® | Relypsa, Inc.
http://www.relypsa.com/about
First New Medicine for the Treatment of Hyperkalemia in More than 50 Years. VELTASSA (patiromer) for oral suspension is the first commercialized medicine resulting from Relypsa’s polymer technology platform. Indication and Limitations of Use. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. Please see Important Safety Information. Avoid use of Veltassa ...
Careers | Relypsa, Inc.
http://www.relypsa.com/careers/job-opportunities
Relypsa is committed to excellence and innovation in every aspect of its science and business. Within an exciting collaborative research and development environment, we offer competitive compensation and benefits. We are seeking world-class professionals who are looking for great opportunities and career growth while providing exceptional contributions to the organization. Relypsa is an equal opportunity employer. Sorry, your browser doesn't seem to support Iframes! Our Innovative Polymer Science.
Partner with Us | Relypsa, Inc.
http://www.relypsa.com/partners
In-Licensing of External Technologies. We have built a company that is passionate about excellence. We have established highly-skilled teams with capabilities in clinical development, manufacturing and commercial operations. We are interested in evaluating opportunities outside the company that could benefit from our expertise and advance our goal of improving patients’ lives. Out-Licensing of Internal Technologies. Charitable Contributions and Sponsorships. Our Innovative Polymer Science. Hane Chow, Inc.
Management
http://www.relypsa.com/about/management
John A. Orwin. Kristine M. Ball. Senior Vice President and Chief Financial Officer. Senior Vice President and Chief Medical Officer. Mary E. Corbett. Senior Vice President, Human Resources. Senior Vice President and Chief Commercial Officer. Stephen D. Harrison. Senior Vice President and Chief Scientific Officer. Ronald A. Krasnow. Senior Vice President and General Counsel. Senior Vice President, Chief Technology Officer. Vice President, Corporate Communications and Investor Relations. Hane Chow, Inc.
TOTAL LINKS TO THIS WEBSITE
65
investor.redwoodcapitalbank.com
IRWeblink
Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.
Investor Relations | Latest information on Regeneron Pharmaceuticals
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health. Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries. Volume 1,032,849. Regener...
Renewable Energy Group, Inc. - Investor Relations
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Renewable Energy Group, Inc.'s financial performance into perspective. To receive E-mail Alerts. View all ». Mar 15, 2018. Renewable Energy Group Announces Changes to Board of Directors. Mar 8, 2018. Renewable Energy Group Reports Fourth Quarter and Full Year 2017 Financial Results. Special Meeting of Stockholders. Share this on (?
Investor Relations | Investor Relations | Regal Theatres
Find Theatre and Showtimes. Jul 30, 2015. Regal Entertainment Group Reports Results for Fiscal Second Quarter 2015 and Declares Quarterly Dividend. Jul 15, 2015. Regal Entertainment Group Announces Timing of Fiscal Second Quarter 2015 Earnings Release and Conference Call. May 27, 2015. Regal Entertainment Group to Participate in Investor Conference in New York. May 18, 2015. Regal Entertainment Group Announces Limited Edition Pin Giveaway To Celebrate the Opening of "Tomorrowland". Regal Entertainment Gr...
Investor Relations | Reis, Inc.
Skip to main navigation. For more information regarding Reis’s products and services, visit www.reis.com. And www.ReisReports.com. Mar 08, 2018. Reis, Inc. to Explore Strategic Alternatives. Mar 08, 2018. Reis, Inc. Announces Fourth Quarter and Full-Year 2017 Financial Results. Mar 08, 2018 at 11:00 am EST. Reis, Inc. Fourth Quarter 2017 Financial Results Call. Jan 17, 2018. 20th Annual Needham Growth Conference. View all events and presentations. 1185 Avenue of the Americas. New York, NY 10036.
Investor Relations - Relypsa, Inc.
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Relypsa, Inc.'s financial performance into perspective. 038 ( 1.53%). 4:00 PM ET on Aug 17, 2015. Delayed at least 20 minutes. Aug 10, 2015. Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States. Aug 10, 2015. View all press releases ». Aug 11, 2015 at 9:45 AM ET. 2015 Wedbush PacGrow Healthcare Conference. Hane Chow, Inc.
Company Overview | RenaissanceRe
RenaissanceRe Specialty Risks Ltd. Top Layer Reinsurance Ltd. Renaissance Reinsurance of Europe. Renaissance Reinsurance Ltd. (Singapore Branch). DaVinci Reinsurance Ltd. (Singapore Branch). RenaissanceRe Syndicate Management Limited. Renaissance Reinsurance U.S. Inc. RenaissanceRe Specialty U.S. Ltd. Tropical Cyclone Forecasting And Risk Analysis. The RenaissanceRe Wall of Wind. AeroEdge Vortex Suppresion Technology. Climate Change: The WPC View. Casualty and Specialty Reinsurance. RenaissanceRe Reports...
Rent-A-Center: Investors: Investor Relations
Aug 7, 2015 4:00 pm. Market leader in a growing industry with compelling fundamentals. Focused on providing affordable, high-quality products to our customers which improve their standard of living. Advantaged business model that delivers superior profitability. Refining our capabilities to enable a better customer experience in the Core business. Executing on a set of significant growth initiatives within AcceptanceNow. A proven track record of returning capital to shareholders. 160;at 8:30 am ET.
Rentrak Corporation - Investor Relations
International Box Office Essentials. Studio Revenue Share Essentials. Movies and TV Everywhere. International Box Office Essentials. Digital Download Essentials Industry. Movie Studios and Distributors. Rentrak in the News. View all ». Rentrak Announces Official Worldwide Box Office Results for Weekend of August 9, 2015. Rentrak Cross-Platform Entertainment Rankings. View all ». 08/10/2015 at 5:00 PM. Q1 2016 Rentrak Corporation Earnings Conference Call. Brean Global Technology Conference. Oct 9, 2014.
Home - Tier 1 Investor Visa | Residency Invest
44 (0)20 3637 0087 wechat: residencyinvest 1 Fore Street, Moorgate, London, EC2Y 9DT. Tier 1 Investor Visa UK. Tier 1 Investor Visa Process. Evidence of Investment Funds. Tier 1 Investor Visa Links. USA EB-5 Investor Visa. Citizenship by Investment Specialists. United Kingdom : Tier 1 Investor Visa. USA : EB-5 Investor Visa. EU Passport in 3 Months. Luxury Real Estate Services. Professional assessment of your family situation before advising you on the right program. We believe in developing highly trust...
ResMed - Investor relations
Stock quote and chart. Stock quote and chart. For Patients and Families. All countries and languages. March 29, 2018. Stock quote and chart. March 29, 2018. Adjusted EPS growth over the last five fiscal years. Free cash flow returned to shareholders over the last rolling five years. ResMed Respiratory Medicine 101. March 29, 2018. ResMed to Announce Third Quarter Fiscal Year 2018 Results. January 22, 2018. ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018. January 8, 2018.
SOCIAL ENGAGEMENT